Calliditas Therapeutics AB (CALT)
Stock Price:
$23.80 USD
-1.00 (-4.03%)
Updated Sep 18, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
592.98M |
| Revenue (ttm) |
21.13M |
| Net Income (ttm) |
-3.73M |
| Shares Out |
24.92M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Sep 18, 2020 |
| Last Price |
$23.80 |
| Previous Close |
$24.80 |
| Change ($) |
-1.00 |
| Change (%) |
-4.03% |
| Day's Open |
24.73 |
| Day's Range |
23.59 - 25.91 |
| Day's Volume |
22,111 |
| 52-Week Range |
19.00 - 28.38 |
More Stats
| Market Cap |
592.98M |
| Enterprise Value |
506.82M |
| Earnings Date (est) |
Nov 12, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
24.92M |
| Float |
24.34M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
-0.35 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3,798 |
| Short Ratio |
1.13 |
| Short % of Float |
0.00% |
| Beta |
1.19 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
28.06 |
| PB Ratio |
3.82 |
| Revenue |
21.13M |
| Operating Income |
-3.20M |
| Net Income |
-3.73M |
| Free Cash Flow |
-8.13M |
| Net Cash |
86.17M |
| Net Cash / Share |
3.46 |
| Gross Margin |
100.00% |
| Operating Margin |
-15.16% |
| Profit Margin |
-17.60% |
| FCF Margin |
-38.48% |
| ROA |
-11.94% |
| ROE |
-19.02% |
| ROIC |
938.10% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
5 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$45.34*
(90.50% upside)
Low
37.6
Current: $23.80
High
56.0
Target: 45.34
*Average 12-month USD price target from 5 stock analysts.
Financial Performance
Financial numbers in millions SEK.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | 185 | - |
| Gross Profit | 185 | - |
| Operating Income | -28.02 | -132 |
| Net Income | -32.58 | -132 |
| Shares Outstanding | 46.30 | - |
| Earnings Per Share | -1.76 | -10.18 |
| Operating Cash Flow | -71.01 | -128 |
| Capital Expenditures | -0.12 | - |
| Free Cash Flow | -71.13 | -128 |
| Cash & Equivalents | 754 | 646 |
| Net Cash / Debt | 754 | 646 |
| Assets | 845 | 648 |
| Liabilities | 57.13 | 30.24 |
| Book Value | 788 | 618 |
Numbers in millions SEK, except per-share numbers.
Company Details
| Full Name |
Calliditas Therapeutics AB |
| Country |
Sweden |
| Employees |
21 |
| CEO |
Renée Julie Elisabet Aguiar-Lucander |
Stock Information
| Ticker Symbol |
CALT |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
NASDAQ: CALT |
| IPO Date |
June 5, 2020 |
Description
Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. The company was founded in 2004 and is headquartered in Stockholm, Sweden. Address: Kungsbron 1, C8, Stockholm, Sweden, 111 22